CBS 2019
CBSMD教育中心
English

充血性心力衰竭

科研文章

荐读文献

Heart Failure With Mid-Range (Borderline) Ejection Fraction: Clinical Implications and Future Directions Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF Association of Left Ventricular Systolic Function With Incident Heart Failure in Late Life A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF) Percutaneous Atriotomy for Levoatrial–to–Coronary Sinus Shunting in Symptomatic Heart Failure: First-in-Human Experience Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction SPECT and PET in ischemic heart failure Association of Cardiovascular Disease With Respiratory Disease Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction Permanent pacemaker use among patients with heart failure and preserved ejection fraction: Findings from the Acute Decompensated Heart Failure National Registry (ADHERE) National Registry

Original Research2021 Jun 12;cvab202.

JOURNAL:Cardiovasc Res. Article Link

AIM2-driven inflammasome activation in heart failure

Z Onódi, M Ruppert, D Kucsera et al. Keywords: canakinumab; cardiomyopathy; drug repurposing; heart failure; inflammation; probenecid

Full Text PDF